PF-06263276

• UNSPSC Description:

  PF-06263276 (PF 6263276) is a potent and selective pan-JAK inhibitor, with IC50s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively[1].

• Target Antigen:

  JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pf-06263276.html

• Purity:

  99.38

• Solubility:

  DMSO : 33.33 mg/mL (ultrasonic)

• Smiles:

  FC1=C(O)C=C(CC)C(C2=CC(NN=C3C4=NC5=C(CN(C(C6=NC=C(N7CCCCC7)N=C6)=O)CC5)N4)=C3C=C2)=C1

• Molecular Weight:

  566.63

• References & Citations:

  [1]Jones P, et al. Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. J Med Chem. 2017 Jan 26;60(2):767-786.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 1

• CAS Number:

  1421502-62-6